Germany's BioNTech to buy CureVac to boost cancer research / Photo: ANDRE PAIN - AFP
-
Over 30 dead as northern China hit by heavy rain, landslides
-
Turkey's glaciers fall victim to climate change
-
'Happy people': folk festivals punctuate Greek summer life
-
Afghans show solidarity as migrant returns from Iran surge
-
O'Callaghan closes on more world gold to banish post-Paris blues
-
Five dead including gunman in New York office shooting spree
-
Destructive Dwarshuis gives Australia 5-0 sweep of West Indies T20s
-
Ill-equipped and tired: a night with a Ukrainian air defence unit
-
Five dead including gunman in New York office shooting
-
Stock markets fall as trade relief fades, eyes on data and earnings
-
'Food on table' outweighs health risks for Philippine e-waste dismantlers
-
'Absolute madness': Thailand's pet lion problem
-
Heavy rain leaves 30 dead in Chinese capital
-
Villagers win race to save UK pub, as thousands close
-
AI bands signal new era for music business
-
Colombian ex-president Uribe guilty of witness tampering
-
Palantir, the AI giant that preaches US dominance
-
Five dead after New York Midtown shooting: US media
-
Thai army accuses Cambodia of breaking truce
-
Heavy rains leave 30 dead in Chinese capital
-
Gunman dead in New York after Midtown shooting: police
-
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
-
Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory
-
Colombian ex-president Uribe found guilty of witness tampering
-
Osaka to work with Wiktorowski on trial after Mouratoglou split
-
Alvaro Uribe: Colombia's first ex-president convicted of a crime
-
Aussie qualifier schools young gun Fonseca in Toronto
-
Second Guardians pitcher on leave under MLB gambling probe
-
China and US wrap first day of trade talks
-
EU car industry sees relief - and pain - in US trade deal
-
Hundreds of Sudanese refugees in Cairo take up chance to return home for free
-
Tinubu receives Nigerian women's team after Africa Cup victory
-
AI Ray-Ban Meta glasses help EssilorLuxottica boost sales
-
Thailand and Cambodia truce agreement comes into effect
-
Europe's carmakers still nervous despite EU-US trade deal
-
China aims for 'reciprocity' in trade talks with US
-
Veteran Vos takes Tour de France yellow after Wiebes stage win
-
Trump warns of 'real starvation' in Gaza as aid deliveries pick up
-
EU defends Trump trade deal in face of backlash
-
England's Lionesses return to heroes' welcome after Euro 2025 glory
-
Hunger must never be 'weapon of war', UN chief tells Africa food summit
-
Heineken shares plummet as beer sales dry up
-
Trump slashes Russia ultimatum to '10 or 12 days'
-
Landslide kills four as rains lash northern China
-
Telegram's Durov questioned in France over alleged illegal content on app
-
Home from home: Trump showcases his resorts in golf diplomacy
-
EU accuses online giant Temu over sale of 'illegal' products
-
'No alternative' to two-state solution for Israel, Palestinians
-
US plan to destroy contraceptives sparks uproar
-
Turkey battles wildfires as heatwave grips Med
NYSE - LSE
| RBGPF | 4.73% | 77.55 | $ | |
| RYCEF | -0.38% | 13.15 | $ | |
| CMSC | 0.07% | 22.5 | $ | |
| RIO | -1.46% | 62.19 | $ | |
| GSK | -1.39% | 37.45 | $ | |
| NGG | -2.6% | 70.32 | $ | |
| BTI | -0.91% | 51.78 | $ | |
| VOD | -2.42% | 11.16 | $ | |
| AZN | -1.16% | 71.83 | $ | |
| SCU | 0% | 12.72 | $ | |
| JRI | -0.46% | 13.03 | $ | |
| BP | 1.44% | 32.67 | $ | |
| SCS | 2.49% | 10.85 | $ | |
| CMSD | 0.04% | 22.9 | $ | |
| RELX | -1.85% | 51.77 | $ | |
| BCC | -1.61% | 86.74 | $ | |
| BCE | -1.55% | 23.83 | $ |
Germany's BioNTech to buy CureVac to boost cancer research
Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.
BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".
Both biotech companies have been working for years in the area of mRNA vaccines and treatments, which provoke an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.
While the technology became well known in relation to some Covid-19 vaccines, it is also being used in other areas, and scientists believe it could be a game-changer against many diseases.
BioNTech said the acquisition of CureVac would help boost its work in the field of mRNA-based cancer immunotherapy -- treatment that uses the body's own immune system to fight diseases.
"This transaction is another building block in BioNTech's oncology strategy and an investment in the future of cancer medicine," said BioNTech CEO Ugur Sahin.
It was aimed at "establishing new standards of care for various types of cancer in the coming years," he said.
Alexander Zehnder, CEO of CureVac, said the purchase would bring scientific expertise, technology and manufacturing know-how "in the mRNA field under one roof".
BioNTech's all-stock acquisition has been unanimously approved by the companies' management and supervisory boards, and is expected to close in 2025, subject to certain conditions including regulatory approvals.
Both companies are listed on the Nasdaq Composite Index.
They had both sought to develop Covid-19 vaccines during the pandemic, with Mainz-based BioNTech's Comirnaty jab winning approval and going on to become one of the most widely used shots against the virus around the world.
But Tuebingen-based CureVac, founded 25 years ago by mRNA pioneer Ingmar Hoerr, abandoned its efforts in late 2021 after disappointing trial results.
In 2022, CureVac sued BioNTech for patent infringement over its rival's use of the technology.
N.Mitchell--AT